Trial Profile
A Randomized, Double-blind, Placebo Controlled Phase I (A) Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacokinetic Characteristics of Supaglutide Injection in Chinese Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Supaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Innogen Pharmaceutical Technology
- 16 Sep 2021 Status changed from active, no longer recruiting to completed.
- 17 Apr 2020 Planned End Date changed from 30 Mar 2020 to 30 May 2020.
- 17 Mar 2020 Planned End Date changed from 17 Dec 2019 to 30 Mar 2020.